{
    "organizations": [],
    "uuid": "58458a950cca69bdebc2be3fd928b7d4a41ff5bc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-european-commission-approves-brist/brief-european-commission-approves-bristol-myers-squibbs-opdivo-4-week-dosing-schedule-idUSFWN1S21EA",
    "ord_in_thread": 0,
    "title": "BRIEF-European Commission Approves Bristol-Myers Squibb's Opdivo 4-Week Dosing Schedule",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Bristol-Myers Squibb Co:\n* EUROPEAN COMMISSION APPROVES BRISTOL-MYERS SQUIBBâ€™S OPDIVO (NIVOLUMAB) FOUR-WEEK DOSING SCHEDULE FOR ADVANCED MELANOMA AND PREVIOUSLY TREATED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-26T04:54:00.000+03:00",
    "crawled": "2018-04-26T21:08:00.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "squibb",
        "co",
        "european",
        "commission",
        "approves",
        "squibb",
        "opdivo",
        "nivolumab",
        "dosing",
        "schedule",
        "advanced",
        "melanoma",
        "previously",
        "treated",
        "renal",
        "cell",
        "carcinoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}